{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05844228",
            "orgStudyIdInfo": {
                "id": "VIR-2218-V108"
            },
            "organization": {
                "fullName": "Vir Biotechnology, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218",
            "officialTitle": "A Phase 1, Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of VIR-2218 in Adult Participants With Renal Impairment",
            "therapeuticArea": [
                "Nephrology and Renal Diseases"
            ],
            "study": "a-study-to-investigate-the-effect-of-renal-impairment-on-the-pharmacokinetics-and-safety-of-vir"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-06-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-05-15",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-11-21",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-04-24",
            "studyFirstSubmitQcDate": "2023-04-24",
            "studyFirstPostDateStruct": {
                "date": "2023-05-06",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-01",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-03",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Vir Biotechnology, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The rationale of this study is to evaluate the impact of renal function on the PK, safety, and tolerability of VIR-2218 in participants with normal renal function and participants with varying degrees of renal dysfunction who are otherwise medically stable",
            "detailedDescription": "Participants may be enrolled in Cohorts 1 and 2 in a non-randomized way."
        },
        "conditionsModule": {
            "conditions": [
                "Renal Impairment"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 32,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Cohort 1: 8 moderate Renal Impairment (RI) participants and 8 matched healthy participants",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: VIR-2218"
                    ]
                },
                {
                    "label": "Cohort 2: 8 severe Renal Impairment (RI) participants and 8 matched healthy participants (optional)",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: VIR-2218"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "VIR-2218",
                    "description": "VIR-2218 given by subcutaneous injection",
                    "armGroupLabels": [
                        "Cohort 1: 8 moderate Renal Impairment (RI) participants and 8 matched healthy participants",
                        "Cohort 2: 8 severe Renal Impairment (RI) participants and 8 matched healthy participants (optional)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Maximum Observed Plasma Concentration (Cmax) of VIR-2218 and its metabolite AS(N-1)3'VIR-2218",
                    "timeFrame": "5 days"
                },
                {
                    "measure": "Area Under The Plasma Concentration-time Curve from Time Zero to Time of Last Quantifiable Concentration (AUClast) of VIR-2218 and metabolite AS(N-1)3'VIR-2218",
                    "timeFrame": "5 days"
                },
                {
                    "measure": "Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf) of VIR-2218 metabolite AS(N-1)3'VIR-2218",
                    "timeFrame": "5 days"
                },
                {
                    "measure": "Fraction excreted in urine in percentage for VIR-2218 and its metabolite AS(N-1)3'VIR-2218",
                    "timeFrame": "5 days"
                },
                {
                    "measure": "Amount excreted in urine for VIR-2218 and its metabolite AS(N-1)3'VIR-2218",
                    "timeFrame": "5 days"
                },
                {
                    "measure": "Renal clearance for VIR-2218 and its metabolite AS(N-1)3'VIR-2218",
                    "timeFrame": "5 days"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)",
                    "timeFrame": "8 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria for All Participants:\n\n* Participants must have stable renal function as defined by less than 20% change in estimated glomerular filtration rate (eGFR) between the first and second screening sample with the first screening visit occurring within 28 days prior to dosing on Day 1 and the second screening visit occurring no more than 14 days apart, but at least 72 hours apart from the first.\n* Body mass index (BMI) within the range 18.5 to 35.0 kg/m2 at screening.\n* Female and Male participants must consent to follow contraception requirements\n* Capability of giving signed informed consent form\n\nInclusion Criteria: Additional Criteria Specific to Healthy Participants:\n\n* Must be in the opinion of the investigator, be in good health based upon medical history, vital signs, physical examination, and screening laboratory evaluations\n* Must have normal renal function as defined by eGFR \u2265 90 mL/min/1.73m2 based on the Modification of Diet in Renal Disease (MDRD) equation determined from the mean of two measurements of serum creatinine at screening.\n\nInclusion Criteria: Additional Criteria Specific to Participants with Renal Impairment\n\n* Participants must, in the opinion of the investigator, be sufficiently healthy for study participation based on medical history, physical examination, vital signs, and screening laboratory evaluations\n* Participants with RI must have chronic moderate or severe RI and be clinically stable per investigator assessment for at least 3 months prior to screening\n* Moderate RI as defined by eGFR level 30-59 mL/min/1.73m2 based on the MDRD equation, or\n* Severe RI as defined by eGFR level 15-29 mL/min/1.73m2 based on the MDRD equation\n\nExclusion Criteria: Criteria for All Participants\n\n* Any clinically significant medical condition or psychiatric condition that may interfere with study intervention\n* Participants with uncontrolled hypertension, asthma, and/or diabetes (Type I or II).\n* Participants with diabetes\n* Participants with any active malignancy\n* Participants with vasculitis or conditions associated with vasculitis.\n* Participants who have undergone major surgery within 12 months of screening\n* Participants with unstable cardiac functions, abnormality, or clinically significant heart failure\n* Participants with infection of HIV, HAV, HBV, HCV, HDV, or HEV\n* Participants with signs of active infection\n* History of bone marrow or solid organ transplantation\n* Participants with end-stage renal disease or nephrotic syndrome as defined by: participants requiring hemodialysis or peritoneal dialysis, participants who have undergone or are listed for transplant, or participants who have chronic kidney disease with nephrotic syndrome\n* Participants with active nephritis\n* Participants with clinically significant liver disease\n* History of drug or alcohol abuse\n* Unwillingness or inability to follow procedures outlined in protocol\n\nExclusion Criteria: Additional Criteria Specific to Healthy Participants\n\n* Use of any prescription medications or over-the-counter medications (with the exception of vitamins and/or hormonal contraceptive medications) including herbal products within 30 days prior to D1 of study participation\n\nExclusion Criteria: Additional Criteria Specific to Participants with Renal Impairment\n\n* Not on stable dose and regimen of any medication(s) (prescription or over-the-counter) that the participants is taking regularly (eg, medications for chronic conditions such as hypertension, high cholesterol, or depression must not be changed in dose or type for at least 2 weeks prior to study drug administration)",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "70 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "locations": [
                {
                    "facility": "Inland Empire Clinical Trials",
                    "status": "RECRUITING",
                    "city": "Rialto",
                    "state": "California",
                    "zip": "92377",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Amanda Benavides",
                            "role": "CONTACT",
                            "phone": "909-883-2999",
                            "phoneExt": "148",
                            "email": "abenavides@ieliverfoundation.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.1064,
                        "lon": -117.37032
                    }
                },
                {
                    "facility": "Floridian Clinical Research",
                    "status": "RECRUITING",
                    "city": "Miami Lakes",
                    "state": "Florida",
                    "zip": "33016",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Angel Benites",
                            "role": "CONTACT",
                            "phone": "305-330-9977",
                            "phoneExt": "124",
                            "email": "aabenitez@floridiancr.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 25.90871,
                        "lon": -80.30866
                    }
                },
                {
                    "facility": "Orlando Clinical Research Center",
                    "status": "RECRUITING",
                    "city": "Orlando",
                    "state": "Florida",
                    "zip": "32809",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Kaylyn Moody",
                            "role": "CONTACT",
                            "phone": "407-472-0139",
                            "email": "kmoody@ocrc.net"
                        }
                    ],
                    "geoPoint": {
                        "lat": 28.53834,
                        "lon": -81.37924
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000051437",
                    "term": "Renal Insufficiency"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007674",
                    "term": "Kidney Diseases"
                },
                {
                    "id": "D000014570",
                    "term": "Urologic Diseases"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M26718",
                    "name": "Renal Insufficiency",
                    "asFound": "Renal Impairment",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10698",
                    "name": "Kidney Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M17319",
                    "name": "Urologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}